Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

BIOCOM : revenue, balance sheet and financial ratios

BIOCOM is a French company founded 16 years ago, specialized in the sector Commerce de gros (commerce interentreprises) d'autres biens domestiques . Based in VEUREY-VOROIZE (38113), this company of category PME shows in 2023 a net income positive of 14 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - BIOCOM (SIREN 518875372)
Indicator 2023
Revenue N/C
Net income 14 035 €
EBITDA N/C
Net margin N/C

Revenue and income statement

In 2023, BIOCOM generates positive net income of 14 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

14 035 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 12%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 41%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

11.757%

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

41.293%

Asset age ratio (2023) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

71.6%

Solvency indicators evolution
BIOCOM

Sector positioning

Debt ratio
11.76 2023
2023
Q1: 0.15
Med: 18.97
Q3: 67.19
Good

In 2023, the debt ratio of BIOCOM (11.76) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.

Financial autonomy
41.29% 2023
2023
Q1: 15.58%
Med: 39.16%
Q3: 61.26%
Good

In 2023, the financial autonomy of BIOCOM (41.3%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 173.70. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

173.703

Liquidity indicators evolution
BIOCOM

Sector positioning

Liquidity ratio
173.7 2023
2023
Q1: 150.77
Med: 236.31
Q3: 432.28
Average

In 2023, the liquidity ratio of BIOCOM (173.70) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Positioning of BIOCOM in its sector

Comparison with sector Commerce de gros (commerce interentreprises) d'autres biens domestiques

Valuation estimate

Based on 145 transactions of similar company sales (all years), the value of BIOCOM is estimated at 46 609 € (range 9 370€ - 83 340€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2023
145 transactions
9k€ 46k€ 83k€
46 609 € Range: 9 370€ - 83 340€
NAF 5 all-time

Valuation method used

Net Income Multiple
14 035 € × 3.3x = 46 609 €
Range: 9 371€ - 83 340€

Only this financial indicator is available for this company.

How is this estimate calculated?

This estimate is based on the analysis of 145 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) d'autres biens domestiques )

Compare BIOCOM with other companies in the same sector:

Frequently asked questions about BIOCOM

What is the revenue of BIOCOM ?

The revenue of BIOCOM is not publicly disclosed (confidential accounts filed with INPI).

Is BIOCOM profitable?

Yes, BIOCOM generated a net profit of 14 k€ in 2023.

Where is the headquarters of BIOCOM ?

The headquarters of BIOCOM is located in VEUREY-VOROIZE (38113), in the department Isere.

Where to find the tax return of BIOCOM ?

The tax return of BIOCOM is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does BIOCOM operate?

BIOCOM operates in the sector Commerce de gros (commerce interentreprises) d'autres biens domestiques (NAF code 46.49Z). See the 'Sector positioning' section above to compare the company with its competitors.